{"id":"NCT04578496","sponsor":"Clinuvel Pharmaceuticals Limited","briefTitle":"A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)","officialTitle":"A Phase III, Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07-11","primaryCompletion":"2014-02-27","completion":"2014-02-27","firstPosted":"2020-10-08","resultsPosted":"2020-11-02","lastUpdate":"2020-11-19"},"enrollment":16,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Erythropoietic Protoporphyria"],"interventions":[{"type":"DRUG","name":"Afamelanotide","otherNames":[]}],"arms":[{"label":"Afamelanotide","type":"EXPERIMENTAL"}],"summary":"The main objectives of the study were to evaluate the safety and tolerability of afamelanotide by measuring treatment emergent adverse events (AEs) and to determine whether afamelanotide can improve the quality of life of EPP patients.","primaryOutcome":{"measure":"Change in Quality of Life Measured Using the EPP-quality of Life Questionnaire (EPP-QoL).","timeFrame":"Baseline, Day 60, Day 120, Day 180 or early termination (ET) (if applicable)","effectByArm":[{"arm":"Afamelanotide","deltaMin":27.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Headache"]}}